NO20074639L - Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin - Google Patents

Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Info

Publication number
NO20074639L
NO20074639L NO20074639A NO20074639A NO20074639L NO 20074639 L NO20074639 L NO 20074639L NO 20074639 A NO20074639 A NO 20074639A NO 20074639 A NO20074639 A NO 20074639A NO 20074639 L NO20074639 L NO 20074639L
Authority
NO
Norway
Prior art keywords
phenylindan
dimethylpiperazine
chloro
trans
crystalline base
Prior art date
Application number
NO20074639A
Other languages
English (en)
Other versions
NO339863B1 (no
Inventor
Benny Bang-Andersen
Heidi Lopez De Diego
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074639(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20074639L publication Critical patent/NO20074639L/no
Publication of NO339863B1 publication Critical patent/NO339863B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Krystallinsk base av forbindelse trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin, fremgangsmåter for fremstillingen av renset fri base eller salter av denne forbindelse, farmasøytiske sammensetninger omfattende basen og medisinsk anvendelse derav, inklusive for behandling av schizofreni og andre psykotiske lidelser.
NO20074639A 2005-02-16 2007-09-12 Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin NO339863B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500239 2005-02-16
PCT/DK2006/000088 WO2006086986A1 (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (2)

Publication Number Publication Date
NO20074639L true NO20074639L (no) 2007-09-12
NO339863B1 NO339863B1 (no) 2017-02-13

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074639A NO339863B1 (no) 2005-02-16 2007-09-12 Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Country Status (29)

Country Link
US (2) US7648991B2 (no)
EP (1) EP1853576B1 (no)
JP (1) JP5055135B2 (no)
KR (1) KR101386387B1 (no)
CN (1) CN101119983B (no)
AR (1) AR052909A1 (no)
AT (1) ATE515501T1 (no)
AU (1) AU2006215957B9 (no)
BR (1) BRPI0607436B8 (no)
CA (1) CA2597622C (no)
CY (1) CY1111857T1 (no)
DK (1) DK1853576T3 (no)
EA (1) EA017631B1 (no)
ES (1) ES2368786T3 (no)
HK (1) HK1117525A1 (no)
HR (1) HRP20110645T1 (no)
IL (1) IL184551A (no)
MX (1) MX2007009980A (no)
MY (1) MY148683A (no)
NO (1) NO339863B1 (no)
NZ (1) NZ556397A (no)
PL (1) PL1853576T3 (no)
PT (1) PT1853576E (no)
RS (1) RS51944B (no)
SI (1) SI1853576T1 (no)
TW (1) TWI376373B (no)
UA (1) UA95901C2 (no)
WO (1) WO2006086986A1 (no)
ZA (1) ZA200705982B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772240B2 (en) * 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
AU2009243813B2 (en) * 2008-05-07 2014-05-29 H. Lundbeck A/S Method for treating cognitive deficits
KR20110081176A (ko) * 2008-10-03 2011-07-13 하. 룬드벡 아크티에셀스카브 경구용 제형물
WO2012176066A1 (en) 2011-06-20 2012-12-27 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
CN112930341A (zh) 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
DE3139970A1 (de) 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
DK0612244T3 (da) 1991-11-05 2002-01-14 Smithkline Beecham Corp Endothelinreceptorantagonister
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
US5750794A (en) 1993-11-30 1998-05-12 Pfizer Inc. Process for preparing chiral tetralone
CA2132411A1 (en) 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
EP1073618B1 (en) * 1998-05-01 2003-12-03 Pfizer Products Inc. Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography
NZ508790A (en) 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (no) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法

Also Published As

Publication number Publication date
BRPI0607436B8 (pt) 2021-05-25
UA95901C2 (en) 2011-09-26
EP1853576A1 (en) 2007-11-14
RS51944B (en) 2012-02-29
US7648991B2 (en) 2010-01-19
US8450324B2 (en) 2013-05-28
MY148683A (en) 2013-05-31
PL1853576T3 (pl) 2011-12-30
HRP20110645T1 (hr) 2011-10-31
CY1111857T1 (el) 2015-11-04
DK1853576T3 (da) 2011-09-26
US20100105699A1 (en) 2010-04-29
SI1853576T1 (sl) 2011-11-30
IL184551A (en) 2014-05-28
JP5055135B2 (ja) 2012-10-24
AU2006215957B9 (en) 2012-02-16
CA2597622A1 (en) 2006-08-24
CN101119983A (zh) 2008-02-06
ES2368786T3 (es) 2011-11-22
TWI376373B (en) 2012-11-11
ATE515501T1 (de) 2011-07-15
KR20070103414A (ko) 2007-10-23
CN101119983B (zh) 2014-11-12
AR052909A1 (es) 2007-04-11
HK1117525A1 (en) 2009-01-16
NO339863B1 (no) 2017-02-13
ZA200705982B (en) 2009-06-24
BRPI0607436A2 (pt) 2010-04-06
KR101386387B1 (ko) 2014-04-25
EA017631B1 (ru) 2013-02-28
PT1853576E (pt) 2011-09-28
US20080153848A1 (en) 2008-06-26
WO2006086986A1 (en) 2006-08-24
AU2006215957A1 (en) 2006-08-24
IL184551A0 (en) 2007-10-31
BRPI0607436B1 (pt) 2020-10-06
MX2007009980A (es) 2007-09-26
AU2006215957B2 (en) 2011-09-29
TW200640890A (en) 2006-12-01
JP2008530040A (ja) 2008-08-07
CA2597622C (en) 2013-11-12
NZ556397A (en) 2010-06-25
EA200701740A1 (ru) 2007-12-28
EP1853576B1 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
NO20045589L (no) Nye forbindelser
NO20084328L (no) Nye forbindelser
NO20055219L (no) Nye forbindelser
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
GEP20156239B (en) Benzofuranyl derivatives used as glucokinase inhibitors
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
SE0301009D0 (sv) Novel compounds
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

MM1K Lapsed by not paying the annual fees